The North America Interventional Pulmonology Market would witness market growth of 5.8% CAGR during the forecast period (2023-2029).
In recent years, bronchoscopy and thoracoscopy have gained popularity as minimally invasive surgical procedures. These techniques reduce the likelihood of surgical problems and provide a quicker recovery for the patient. In addition, the introduction of novel drugs and therapies for respiratory problems has significantly impacted the market share of interventional pulmonology. Asthma and chronic obstructive pulmonary disease, for instance, are increasingly treated with monoclonal antibodies and other biological treatments, including monoclonal antibodies.
Technological advancements are also anticipated to substantially impact the expansion of the interventional pulmonology market share over the forecast period, leading to improved patient outcomes and a rise in demand for interventional pulmonology services. In the interventional pulmonology market, robotic bronchoscopy is becoming a game-changer. Businesses are expected to work with researchers to develop revolutionary robotic bronchoscopy platforms that enable pulmonologists to see and access lung lesions without invasive surgery.
According to the Centers for Disease Control and Prevention, 16 million Americans have been diagnosed with chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis. In addition, millions more people have COPD but have not received a diagnosis or treatment. In Canada, 2.0 million people had the chronic obstructive pulmonary disease in 2019. (COPD). Additionally, the CDC reports that 3.08 million middle and high school adolescents use at least one tobacco product, primarily e-cigarettes and that nearly 40 million American adults still smoke cigarettes. Almost 1,600 American teenagers under the age of 18 light up their first cigarette every day. As a result, North America has greater growth prospects for interventional pulmonology.
The US market dominated the North America Interventional Pulmonology Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,628.5 million by 2029. The Canada market is poised to grow at a CAGR of 8.2% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 7.2% during (2023 - 2029).
Based on Product, the market is segmented into Bronchoscopes, Electromagnetic Navigation Bronchoscopy System, Bronchial Thermoplasty Systems, Pleuroscopes, Respiratory Endotherapy Devices, Endobronchial Valves and Airway Stents & Pleural Catheters. Based on Indication, the market is segmented into Asthma, Lung Cancer, COPD, Tracheal & Bronchial Stenosis and Others. Based on End-user, the market is segmented into Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Specialty Clinics and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Interventional Pulmonology Market is Projected to reach USD 5.9 Billion by 2029, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Boston Scientific Corporation, Becton, Dickinson and Company, Olympus Corporation, Fujifilm Holdings Corporation, ICU Medical, Inc. (Smiths Medical), HUGER Medical Instrument Co., Ltd, Cook Medical, Inc. (Cook Group), Clarus Medical LLC and Vygon SAS.
By Product
By Indication
By End-user
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 